

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-14. (canceled)

15. (currently amended) A liquid concentrate preservative which comprises:

- a) 3-iodo-2-propynyl butylcarbamate (IPBC);
- b) at least one liquid carrier; and
- c) at least one stabilizer,

wherein no additional carboxylic acid chosen from benzoic acid, propionic acid, salicylic acid, sorbic acid, 4-hydroxybenzoic acid, dehydroacetic acid, and 10-undecylenic acid, or the salts thereof, is present.

16. (cancelled)

17. (previously presented) The concentrate according to Claim 15, wherein the weight of said IPBC comprises from about 0.01% to about 20% of the concentrate's weight.

18. (previously presented) The concentrate according to Claim 17, wherein said weight comprises up to about 5% of the concentrate's weight.

19. (previously presented) The concentrate according to Claim 18, wherein said weight comprises up to about 2% of the concentrate's weight.

20. (previously presented) The concentrate according to Claim 19, wherein said weight comprises up to about 1% of the concentrate's weight.

21. (previously presented) The concentrate according to Claim 15, wherein said liquid carrier comprises at least one component selected from the group consisting of:

- a) polyvalent alcohols;
- b) glycol esters; and
- c) glycol ethers.

22. (previously presented) The concentrate according to Claim 21, wherein said polyvalent alcohol is at least one component selected from the group consisting of:

- a) diol;
- b) glycol;
- c) ethylene glycol;
- d) 1,2-propylene glycol;
- e) 1,3-propylene glycol;
- f) 1,2-butylene glycol;
- g) 1,3-butylene glycol;
- h) 1,4-butylene glycol;
- i) 1,2-pentanediol;
- j) 1,3-pentanediol;
- k) 1,4-pentanediol;
- l) 1,5-pentanediol;
- m) glycol ester;

- n) glycol ether;
- o) ethylene glycol;
- p) propylene glycol;
- q) butylene glycol;
- r) diethylene glycol;
- s) triethylene glycol;
- t) polyethylene glycol;
- u) triethylene glycol; and
- v) 1,2-propylene glycol.

23. (previously presented) The concentrate according to Claim 15, wherein said stabilizer comprises at least one component selected from the group consisting of:

- a) formic acid;
- b) formate salts;
- c) formate esters;
- d) sodium formate;
- e) potassium formate; and
- f) formic acid propylene glycol mono-, diester, and formate esters formed in situ.

24. (previously presented) The concentrate according to Claim 23, wherein said stabilizer consists of formic acid.

25. (previously presented) The concentrate according to Claim 15, wherein the weight of said stabilizer comprises from about 0.001% to about 20% of the concentrate's weight.

26. (previously presented) The concentrate according to

Claim 25, wherein said weight comprises up to about 10% of the concentrate's weight.

27. (previously presented) The concentrate according to Claim 26, wherein said weight comprises up to about 5% of the concentrate's weight.

28. (previously presented) The concentrate according to Claim 27, wherein said weight comprises up to about 2% of the concentrate's weight.

29. (previously presented) The concentrate according to Claim 28, wherein said weight comprises less than about 0.5% of the concentrate's weight.

30. (previously presented) The concentrate according to Claim 29, wherein said weight comprises less than about 0.2% of the concentrate's weight.

31. (currently amended) The concentrate according to Claim 15, wherein said concentrate further comprises a component selected from the group consisting of:

- a) at least one active agent;
- b) at least one functional additive; [[and]]
- c) at least one auxiliary; and
- d) mixtures thereof.

32. (previously presented) The concentrate according to Claim 31, wherein said active agent is polybiguanide, or a polybiguanide salt.

33. (previously presented) The concentrate according to

Claim 32, wherein the weight of said active agent comprises up to about 20% of the concentrate's weight.

34. (previously presented) The concentrate according to Claim 33, wherein said weight comprises up to about 5% of the concentrate's weight.

35. (previously presented) The concentrate according to Claim 34, wherein said weight comprises up to about 2% of the concentrate's weight.

36. (previously presented) The concentrate according to Claim 35, wherein said weight comprises up to about 1% of the concentrate's weight.

37. (previously presented) The concentrate according to Claim 31, wherein the weight ratio of IPBC to said active agent ranges from about 100:1 to about 1:100.

38. (previously presented) The concentrate according to Claim 37, wherein said weight ratio ranges from about 10:1 to about 1:10.

39. (previously presented) The concentrate according to Claim 38, wherein said weight ratio ranges from about 1:2 to about 2:1.

40. (previously presented) The concentrate according to Claim 15, wherein the weight of said IPBC comprises less than about 1% of the concentrate's weight and wherein the weight of said active agent comprises less than about 1% of the concentrate's weight.

41. (previously presented) The concentrate according to Claim 40, wherein said weight of IPBC comprises about 1% of the concentrate's weight and wherein said weight of active agent comprises less than about 1% of the concentrate's weight.

42. (previously presented) The concentrate according to Claim 41, wherein said weight of IPBC comprises about 1% of the concentrate's weight and wherein said weight of active agent comprises about 0.95% of the concentrate's weight.

43. (previously presented) The concentrate according to Claim 42, wherein said weight of IPBC comprises less than about 1% of the concentrate's weight and wherein said weight of active agent comprises about 0.95% of the concentrate's weight.

44. (previously presented) The concentrate according to Claim 15, wherein said concentrate further comprises:

- d) at least one active agent;
- e) at least one functional additive; and
- f) absent an auxiliary.

45. (previously presented) The concentrate according to Claim 31, wherein said auxiliary comprises water.

46. (previously presented) The concentrate according to Claim 45, wherein the weight of said water comprises from about 0.01% to about 10% of the concentrate's weight.

47. (previously presented) The concentrate according to Claim 46, wherein said weight comprises up to about 5% of the concentrate's weight.

48. (previously presented) The concentrate according to Claim 47, wherein said weight comprises up to about 4.5% of the concentrate's weight.

49. (previously presented) The concentrate according to Claim 48, wherein said weight comprises up to about 4% of the concentrate's weight.

50. (previously presented) The concentrate according to Claim 49, wherein said weight comprises up to about 0.2% of the concentrate's weight.

51. (previously presented) The concentrate according to Claim 31, wherein said active agent comprises a paraben.

52. (previously presented) The concentrate according to Claim 51, wherein said paraben is selected from the group consisting of: methyl-, ethyl-, propyl- and butylparaben.

53. (previously presented) The concentrate according to Claim 31, wherein said active agent comprises a quaternary ammonium compound.

54. (previously presented) The concentrate according to Claim 53, wherein said quaternary ammonium compound is polyhexamethylenebiguanide, or the salt thereof.

55. (previously presented) The concentrate according to Claim 31, wherein said active agent comprises a salt.

56. (previously presented) The concentrate according to Claim 55, wherein said salt is at least one component selected from the group consisting of:

- a) benzalkonium salt;
- b) benzalkonium chloride;
- c) formaldehyde;
- d) formaldehyde-depositing compound;
- e) dimethyloldimethylhydantoin (DMDMH);
- f) imidazolidinylurea;
- g) diazolidinylurea;
- h) hexetidine;
- i) 5-bromo-5-nitro-1,3-dioxane (bronidox);
- j) 2-bromo-2-nitro-1,3-propanediol (bronopol);
- k) 1,3,5,7-tetraazaadamantane (hexamethylenetetramine);
- l) 4,4-dimethyl-1,3-oxazolidine;
- m) benzyl alcohol hemiformal;
- n) 5-ethyl-1-aza-3,7-dioxabicyclo[3,3.0]octane;
- o) 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride;
- p) phenoxyethanol;
- q) phenoxypropanol and;
- r) benzyl alcohol; and
- s) the salts thereof.

57. (previously presented) The concentrate according to Claim 31, wherein said active agent comprises a halogen compound.

58. (previously presented) The concentrate according to Claim 57, wherein said halogen compound is dibromodicyanobutane (DBDCB).



59. (previously presented) The concentrate according to Claim 31, wherein said active agent comprises an amidine compound.

60. (previously presented) The concentrate according to Claim 59, wherein said amidine compound is at least one component selected from the group consisting of:

- a) hexamidine;
- b) dibromohexamidine; and
- c) the salts thereof.

61. (previously presented) The concentrate according to Claim 31, wherein said active agent comprises isothiazolone.

62. (previously presented) The concentrate according to Claim 61, wherein said isothiazolone is N-methylisothiazolone, or N-octylisothiazolone.

63. (previously presented) The concentrate according to Claim 31, wherein said active agent comprises at least one component selected from the group consisting of:

- a) paraben;
- b) quaternary ammonium compound;
- c) benzalkonium salt;
- d) halogen compound;
- e) amidine compound; and
- f) isothiazolone,

64. (previously presented) The concentrate according to Claim 63, wherein said paraben comprises at least one component

selected from the group consisting of: methyl-, ethyl-, propyl-, and butylparaben.

65. (previously presented) The concentrate according to Claim 63, wherein said quaternary ammonium compound is polyhexamethylene biguanide, or the salt thereof.

66. (previously presented) The concentrate according to Claim 63, wherein said benzalkonium salt is at least one component selected from the group consisting of:

- a) benzalkonium chloride;
- b) formaldehyde;
- c) formaldehyde-depositing compound;
- d) dimethyloldimethylhydantoin (DMDMH);
- e) imidazolidinylurea;
- f) diazolidinylurea;
- g) hexetidine;
- h) 5-bromo-5-nitro-1,3-dioxane (bronidox);
- i) 2-bromo-2-nitro-1,3-propanediol (bronopol);
- j) 1,3,5,7-tetraazaadamantane (hexamethylenetetramine);
- k) 4,4-dimethyl-1,3-oxazolidine;
- l) benzyl alcohol hemiformal;
- m) 5-ethyl-1-aza-3,7-dioxabicyclo[3.3.0]octane;
- n) 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride;
- o) phenoxyethanol;
- p) phenoxypropanol;

- q) benzyl alcohol; and
- r) the salts thereof.

67. (previously presented) The concentrate according to Claim 63, wherein said halogen compound is dibromodicyanobutane (DBDCB).

68. (previously presented) The concentrate according to Claim 63, wherein said amidine compound, is at least one component selected from the group consisting of:

- a) hexamidine;
- b) dibromohexamidine; and
- c) the salts thereof.

69. (previously presented) The concentrate according to Claim 63, wherein said isothiazolone is N-methylisothiazolonem, or N-octylisothiazolone.

70. (previously presented) The concentrate according to Claim 15, wherein a process for the preparation of a concentrate comprises mixing constituents of the concentrate.

71. (previously presented) The concentrate according to Claim 70, wherein said mixture is subsequently held after mixing for about 0.5 hour to about 48 hours at a temperature from about 30°C to about 70°C.

72. (previously presented) The concentrate according to Claim 71, wherein said temperature ranges from about 30°C to about 60°C.

73. (previously presented) The concentrate according to

Claim 72, wherein said temperature ranges from about 30°C to 50°C.

74. (previously presented) The concentrate according to Claim 15, wherein said concentrate may be utilized for the preparation of cosmetic and pharmaceutical products.

75. (previously presented) The concentrate according to Claim 15, wherein said concentrate may be utilized for the preservation of cosmetic and pharmaceutical products.